Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.

Cabrera MC, Díaz-Cruz ES, Kallakury BV, Pishvaian MJ, Grubbs CJ, Muccio DD, Furth PA.

Cancer Prev Res (Phila). 2012 Jun;5(6):810-21. doi: 10.1158/1940-6207.CAPR-11-0532-T. Epub 2012 Apr 16.

2.

The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.

Paternot S, Colleoni B, Bisteau X, Roger PP.

Cell Cycle. 2014;13(18):2879-88. doi: 10.4161/15384101.2014.946841.

4.

p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.

Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mladek AC, Fink SR, Decker PA, Wu W, Kim JS, Waldman T, Jenkins RB, Sarkaria JN.

Neuro Oncol. 2012 Jul;14(7):870-81. doi: 10.1093/neuonc/nos114. Epub 2012 Jun 18.

5.

Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.

Brookes S, Gagrica S, Sanij E, Rowe J, Gregory FJ, Hara E, Peters G.

Cell Cycle. 2015;14(8):1164-73. doi: 10.1080/15384101.2015.1010866.

6.

Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.

Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T, Caligiuri MA, Briesewitz R.

Blood. 2007 Sep 15;110(6):2075-83. Epub 2007 May 30.

7.

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, Zamboni WC, Wong KK, Perou CM, Sharpless NE.

J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. doi: 10.1093/jnci/djs002. Epub 2012 Feb 1.

8.

Role of cell cycle regulators in tumor formation in transgenic mice expressing the human neurotropic virus, JCV, early protein.

Krynska B, Gordon J, Otte J, Franks R, Knobler R, DeLuca A, Giordano A, Khalili K.

J Cell Biochem. 1997 Nov 1;67(2):223-30.

PMID:
9328827
9.

Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.

Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Graña X, Knudsen ES.

Gastroenterology. 2010 May;138(5):1920-30. doi: 10.1053/j.gastro.2010.01.007. Epub 2010 Jan 25.

10.

Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.

Tang LH, Contractor T, Clausen R, Klimstra DS, Du YC, Allen PJ, Brennan MF, Levine AJ, Harris CR.

Clin Cancer Res. 2012 Sep 1;18(17):4612-20. doi: 10.1158/1078-0432.CCR-11-3264. Epub 2012 Jul 3.

11.

[Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].

Viallard JF, Lacombe F, Belloc F, Pellegrin JL, Reiffers J.

Cancer Radiother. 2001 Apr;5(2):109-29. Review. French.

PMID:
11355576
12.

Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.

Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, Knowles DM, Lane J, Chen-Kiang S.

Cancer Res. 2005 Dec 15;65(24):11345-53.

13.
14.

p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.

Saab R, Rodriguez-Galindo C, Matmati K, Rehg JE, Baumer SH, Khoury JD, Billups C, Neale G, Helton KJ, Skapek SX.

Cancer Res. 2009 Jan 15;69(2):440-8. doi: 10.1158/0008-5472.CAN-08-1892.

15.

Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.

Nemoto A, Saida S, Kato I, Kikuchi J, Furukawa Y, Maeda Y, Akahane K, Honna-Oshiro H, Goi K, Kagami K, Kimura S, Sato Y, Okabe S, Niwa A, Watanabe K, Nakahata T, Heike T, Sugita K, Inukai T.

Mol Cancer Ther. 2016 Jan;15(1):94-105. doi: 10.1158/1535-7163.MCT-14-1065. Epub 2015 Dec 4.

16.

Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein.

Yu B, Lane ME, Pestell RG, Albanese C, Wadler S.

Mol Cell Biol Res Commun. 2000 Jun;3(6):352-9.

PMID:
11032757
18.

Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo.

Ezhevsky SA, Ho A, Becker-Hapak M, Davis PK, Dowdy SF.

Mol Cell Biol. 2001 Jul;21(14):4773-84.

19.
20.

Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb.

Ezhevsky SA, Nagahara H, Vocero-Akbani AM, Gius DR, Wei MC, Dowdy SF.

Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10699-704.

Supplemental Content

Support Center